Advertisement
Document › Details
Orchard Therapeutics Ltd.. (3/6/18). "Press Release: Orchard Therapeutics to Present at the Cowen and Company Annual Healthcare Conference". London.
Region | Boston, MA | |
Country | United States (USA) | |
Organisation | Orchard Therapeutics Ltd. | |
Group | Orchard Therapeutics (Group) | |
Organisation 2 | Cowen & Company LLC | |
Product | Cowen & Co. Annual Health Care Conference 2018 Boston | |
Product 2 | gene therapy | |
Index term | Orchard Therapeutics–Cowen: investor conference, 201803 supply service Orchard presents at Cowen & Co Annual Health Care Conference 2018 | |
Index term 2 | Orchard Therapeutics–LifeSci: public relations, 201712 service existent by LifeSci Public Relations | |
Person | Rothera, Mark (Freeline Therapeutics –202202 CEO before Orchard Therapeutics + PTC Tx + Aegerion + Shire RESIGNED 2/22) | |
Person 2 | Blum, Allison (LifeSci Public Relations 201712) | |
Orchard Therapeutics, a clinical-stage biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, today announced that Mark Rothera, president and chief executive officer, will present at the Cowen & Co. 38th Annual Healthcare Conference on Wednesday, March 14, 2018, at 11:30 a.m. ET in Boston.
About Orchard Therapeutics
Orchard Therapeutics is a privately held clinical-stage biotechnology company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies. Orchard, based in the UK and US, has partnered with world leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital. Orchard’s growing pipeline of autologous ex vivo lentiviral gene therapy programs for rare immune deficiencies and metabolic disorders includes late clinical stage programs that have already demonstrated the transformative power of gene therapy on patients’ lives. In 2016 the company was named a Fierce 15 Company by Fierce Biotech and was awarded a $19 million grant from the California Institute of Regenerative Medicine (CIRM) to advance their autologous ex vivo lentiviral gene therapy in ADA-SCID. In 2017, Orchard raised $110 million in a Series B round of funding to further develop its pipeline in parallel with enhancing manufacturing capabilities.
Contacts
Corporate contact
Nicolas Koebel
Orchard Therapeutics
+44 (0) 203 384 6700
Nicolas.koebel@orchard-tx.com
Media contact
Allison Blum, Ph.D.
LifeSci Public Relations
+1 516 655 0842
Allison@lifescipublicrelations.com
Record changed: 2023-06-05 |
Advertisement
More documents for Orchard Therapeutics (Group)
- [1] Oxford Biomedica plc. (3/18/20). "Press Release: Building the Group for Future Growth. Business Update". Oxford....
- [2] 4BIO Capital (4BIO Ventures Management Ltd.). (9/9/19). "Press Release: 4BIO Capital Raises $50 million in First Close of New Advanced Therapies Fund". London & Boston, MA....
- [3] Orchard Therapeutics Ltd.. (3/27/19). "Press Release: Orchard Therapeutics Presents New Registrational Data Demonstrating Sustained Clinical Benefit of OTL-200 for the Treatment of MLD". Boston, MA & London....
- [4] Orchard Therapeutics Ltd.. (3/21/19). "Press Release: Orchard Therapeutics Reports 2018 Financial Results and Reviews Recent Business Highlights". Boston, MA & London....
- [5] Orchard Therapeutics Ltd.. (3/18/19). "Press Release: Orchard Therapeutics Strengthens Global Manufacturing and Supply Chain Leadership with Appointment of Ran Zheng as Chief Technical Officer". Boston, MA & London....
- [6] Orchard Therapeutics Ltd.. (3/4/19). "Press Release: Orchard Therapeutics to Present at the Cowen 39th Annual Health Care Conference on March 11, 2019". Boston, MA & London....
- [7] Orchard Therapeutics Ltd.. (2/25/19). "Press Release: Orchard Therapeutics Presents Clinical Proof-of-Concept Data for OTL-102 for the Treatment of X-CGD". Boston, MA & London....
- [8] Orchard Therapeutics Ltd.. (2/22/19). "Press Release: Orchard Therapeutics Presents Two-year Follow-up Data Versus Historical Control from Registrational Trial of OTL-101 for the Treatment of ADA-SCID". Boston, MA & London....
- [9] Orchard Therapeutics Ltd.. (1/7/19). "Press Release: Orchard Therapeutics Highlights Recent Accomplishments and 2019 Strategic Priorities as a Global Leader in Gene Therapy". Boston & London....
- [10] Orchard Therapeutics Ltd.. (1/2/19). "Press Release: Orchard Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019". Boston & London....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top